Fortune 500 Executive joins Spherix as Vice President, Licensing

19 March 2014
spherix

Spherix Incorporated (NASDAQ: SPEX), an intellectual property (IP) development company committed to the fostering and monetization of IP, has announced that Frank Reiner, an experienced patent licensing and monetization professional, has joined Spherix as Vice President, Licensing, where he will report to chief executive Anthony Hayes and play a key role in the company's licensing efforts.

Mr Reiner most recently served as the Vice President of Patent Licensing and Acquisition for Flextronics International. Prior to Flextronics, he was a partner at Intellectual Value Creation Services, where he advised the IP Investment Group at Coller Capital on patent monetization, including patent acquisitions, sales and licensing, each from a technical and business perspective. Earlier in his career Mr Reiner served as the Senior Director of Licensing at InterDigital Communications and was responsible for InterDigital's patent licensing program in the cellular and wireless space.

Mr Hayes said: “We are extremely pleased that Frank has joined the Spherix team at this very important time in the company's evolution. Frank brings many years of experience and his skill set in the cellular and wireless space compliments Spherix's portfolio of patents.”

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight